Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 13/20 | 0.58 |
| ▸ | PFKFB3 | Q16875 | 6/20 | 0.57 |
| ▸ | RET | P07949 | 1/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.55 |
| ▸ | KIT | P10721 | 1/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.55 |
| ▸ | FLT1 | P17948 | 1/20 | 0.55 |
| ▸ | FLT4 | P35916 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | FRK | P42685 | 1/20 | 0.55 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.55 |
| ▸ | CASR | P41180 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5208586 | 0.85 | CSF1R (0.47) | CSF1RPFKFB3RETPDGFRBKIT | |
| SCHEMBL5787131 | 0.85 | CSF1R (0.47) | CSF1RPFKFB3RETPDGFRBKIT | |
| SCHEMBL3158061 | 0.85 | CSF1R (0.47) | CSF1RPFKFB3RETPDGFRBKIT | |
| SCHEMBL3473529 | 0.84 | CSF1R (0.58) | CSF1RPFKFB3RETPDGFRBKIT | |
| SCHEMBL3560403 | 0.84 | CSF1R (0.58) | CSF1RPFKFB3RETPDGFRBKIT | |
| SCHEMBL3474925 | 0.84 | CSF1R (0.63) | CSF1RPFKFB3RETPDGFRBKIT | |
| SCHEMBL3473531 | 0.84 | CSF1R (0.58) | CSF1RPFKFB3RETPDGFRBKIT | |
| SCHEMBL13313078 | 0.84 | CSF1R (0.58) | CSF1RPFKFB3RETPDGFRBKIT | |
| SCHEMBL13340239 | 0.83 | CSF1R (0.81) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL1678955 | 0.83 | CSF1R (0.62) | CSF1RRETPDGFRBKITSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329737-B2 | Benzimidazoles as selective kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2012-12-11 | — | — | US | disclosed |
| US-8329737-B2 | Benzimidazoles as selective kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2012-12-11 | — | — | US | disclosed |
| EP-1704145-B1 | SELECTIVE KINASE INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2012-06-13 | — | — | EP | disclosed |
| US-20110082142-A1 | SELECTIVE KINASE INHIBITORS | CYTOPIA RESEARCH PTY LTD (AU) | 2011-04-07 | — | — | US | disclosed |
| US-20110082142-A1 | SELECTIVE KINASE INHIBITORS | CYTOPIA RESEARCH PTY LTD (AU) | 2011-04-07 | — | — | US | disclosed |
| US-20080207613-A1 | Selective Kinase Inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2008-08-28 | — | — | US | disclosed |
| US-20080207613-A1 | Selective Kinase Inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2008-08-28 | — | — | US | disclosed |
| US-20080207613-A1 | Selective Kinase Inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2008-08-28 | — | — | US | disclosed |
| EP-1513821-B1 | PROTEIN KINASE INHIBITORS | CYTOPIA PTY LTD (AU) | 2007-10-31 | — | — | EP | disclosed |
| US-7122550-B2 | Protein kinase inhibitors | CYTOPIA PTY LTD (AU) | 2006-10-17 | — | — | US | disclosed |
| US-20060148824-A1 | Protein kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2006-07-06 | — | — | US | disclosed |
| US-20040235862-A1 | For therapy of atopy, a cell mediated hypersensitivity, a rheumatic disease, an autoimmune disease, a viral disease, and a cancer | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235862-A1 | For therapy of atopy, a cell mediated hypersensitivity, a rheumatic disease, an autoimmune disease, a viral disease, and a cancer | LCK, IRAK1, MAP2K5 | CSF1R 1399/4885PFKFB3 1276/4885RET 963/4885 |
| US-20110082142-A1 | SELECTIVE KINASE INHIBITORS | LCK, CHUK, CSK | CSF1R 671/4885PFKFB3 435/4885RET 219/4885 |
| US-20060148824-A1 | Protein kinase inhibitors | MAP3K20, MAP4K2, MAP3K1 | CSF1R 3034/4885PFKFB3 404/4885RET 437/4885 |
| US-20080207613-A1 | Selective Kinase Inhibitors | LCK, CHUK, CSK | CSF1R 671/4885PFKFB3 435/4885RET 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.